Pfizer provides update on Phase III PALLAS trial of Ibrance + endocrine therapy in HR+, HER 2- early breast cancer.
As announced by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. reports that following a preplanned efficacy and futility analysis,… read more.